Merck Hopes To Make A Success Story of CETP Inhibitors And Obesity Drugs
Executive Summary
Merck is hoping to find success where other firms have failed: its late stage pipeline includes two programs in drug classes where the lead candidates from other companies have not managed to gain approval
You may also be interested in...
“Bio-buck” Deals A Good Risk-Sharing Strategy, Pharma Execs Say At BIO
Bio-buck deals, those back-end-loaded, early-stage collaborations that grab headlines because of the big dollars promised, are a win-win risk share, big pharma execs say
“Bio-buck” Deals A Good Risk-Sharing Strategy, Pharma Execs Say At BIO
Bio-buck deals, those back-end-loaded, early-stage collaborations that grab headlines because of the big dollars promised, are a win-win risk share, big pharma execs say
Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo
Although Merck's cholesterol combination Cordaptive failed to clear FDA on the first pass, the company is clear that FDA's decision does not signal the end of development for the cholesterol drug